Study analysis · Microorganisms · 2026
Your gut bacteria might be deciding if you live to 90—here’s how.
As you get older, the bacteria in your gut change, and those changes affect blood chemicals that can make you more or less likely to die.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study found that older people tend to have different gut bacteria and blood chemicals than younger people, and that some of these chemicals are linked to whether people live longer or not. But it doesn't prove that the bacteria cause the chemicals to change or that changing the bacteria will make you live longer.
What’s the bottom line?
As people get older, the types of bacteria in their gut change, and these bacteria affect chemicals in the blood that can make you more or less likely to die.
How strong is this study?
The scientists used a really good group of healthy older adults and measured their gut bacteria and blood chemicals very carefully. But they didn't change anything or control what people ate or did, so we can't be sure if the bacteria are the cause—or if something else, like diet, is responsible.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
37 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=704)+19.4/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization or intervention; it can identify associations but cannot determine if changes in gut microbiota cause changes in metabolites or mortality, as reverse causation and confounding factors (e.g., diet, medications, lifestyle) cannot be ruled out.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text.
The study was conducted using data from the Baltimore Longitudinal Study of Aging (BLSA), which is supported by the National Institute on Aging (NIA), an entity of the National Institutes of Health (NIH). However, no explicit funding statement or conflict of interest disclosure was provided in the text. The methods describe standard academic protocols and third-party labs (Diversigen, Biocrates) for sequencing and metabolite analysis, with no indication of industry influence on study design, analysis, or publication. No author affiliations with commercial entities are disclosed.
Key takeaways
- 01
6 bacterial types increased with age; 3 blood chemicals lowered death risk; 6 blood chemicals raised death risk.
- 02
Yes—these chemical changes are linked to real differences in how long people live, even among healthy older adults.
Surprising findings
- Gut microbiome diversity increases with age—and that’s linked to longevity.Most assume aging means losing microbial diversity, but here, older, healthier adults had higher diversity—challenging the idea that 'less diversity = aging.'
- Firmicutes at the phylum level decreased with age, but four of the six age-increasing genera were also Firmicutes.This contradicts the simple narrative that Firmicutes = good or bad. The same phylum contains both protective (Faecalibacterium) and harmful (Oscillibacter) players.
- Oscillibacter mediates 102 metabolites—mostly triglycerides—and is the single most influential age-associated genus.No one expected one obscure genus to be the central hub connecting aging, gut bacteria, and 100+ blood chemicals. It’s the puppet master of metabolic aging.
Practical takeaways
Eat more diverse plant fibers to support beneficial genera like Faecalibacterium and possibly suppress Oscillibacter.
This study didn’t test diet interventions—so we can’t say for sure what foods will change these specific bacteria. Also, the cohort was mostly healthy, high-SES individuals.
medium confidenceAvoid over-reliance on broad-spectrum probiotics—some may contain strains that boost harmful taxa like Klebsiella or Escherichia.
No direct evidence here links probiotics to these specific bacteria. This is inference from microbial patterns, not intervention data.
low confidenceFocus on metabolic health markers—triglycerides, bile acids, and sphingolipids—rather than just gut symptoms.
These metabolites require blood tests not available to most consumers. Don’t self-diagnose based on this study.
medium confidenceWhy this study matters
The 6 Age-Boosting Gut Bacteria
The study found six gut bacterial genera that increase with age: Akkermansia, Escherichia, Klebsiella, Methanobrevibacter, Oscillibacter, and Ruthenibacterium. Oscillibacter alone mediates 102 plasma metabolites—mostly triglycerides—linking it directly to mortality risk pathways.
Most people think probiotics or fiber are the keys to gut health, but this shows specific, naturally evolving bacteria—ones you can’t just supplement—are quietly shaping your aging trajectory.
The 3 Blood Chemicals That Save Lives
Three plasma metabolites—Asparagine, Sphingomyelin C26:0, and Dihydroceramide (d18:0/24:1)—were linked to decreased mortality risk. Asparagine, an amino acid, was associated with better insulin sensitivity and lower risk of heart disease and diabetes.
You don’t need expensive supplements—your body may be producing longevity-promoting chemicals based on your gut bugs. This flips the script from 'eat this' to 'grow these bugs.'
Firmicutes: The Gut Phylum That Declines With Age
Firmicutes, once thought to be universally 'good,' decreased with age in this cohort. Yet, within Firmicutes, some genera like Faecalibacterium declined (good), while Oscillibacter rose (bad)—showing phylum-level labels are misleading.
This shatters the myth that 'more Firmicutes = healthier gut.' The truth is messy: it’s not the phylum, it’s the specific species—and some Firmicutes may be aging accelerators.
The Deadly Bile Acid: Glycoursodeoxycholic Acid (GUDCA)
Glycoursodeoxycholic acid (GUDCA), a bile acid produced by gut microbes, was linked to increased mortality risk. It’s produced by Methanobrevibacter and Firmicutes, and prior studies link it to liver cancer and cardiovascular events.
You’ve heard of TMAO as the 'bad' gut metabolite—now GUDCA is the new villain. It’s not diet alone; it’s your gut bugs turning your bile into a death signal.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
As people get older, the types of bacteria in their gut change, and these bacteria affect chemicals in the blood that can make you more or less likely to die.
Research results
6 bacterial types increased with age; 3 blood chemicals lowered death risk; 6 blood chemicals raised death risk.
What this means - more context
Yes—these chemical changes are linked to real differences in how long people live, even among healthy older adults.
This study investigates how age-related changes in the gut microbiome influence plasma metabolites and their association with all-cause mortality in healthy adults aged 27–98.
The study identifies age-associated shifts in gut microbial phyla and genera, which mediate changes in plasma metabolites—including bile acids, triglycerides, and phosphatidylcholines—linked to mortality risk. Three metabolites (Asparagine, Sphingomyelin C26:0, Dihydroceramide d18:0/24:1) were protective, while six (e.g., Glycoursodeoxycholic acid, specific triglycerides) increased mortality risk.
Methods Used
Observational cohort study of 704 participants from the Baltimore Longitudinal Study of Aging (BLSA) with shotgun metagenomics for gut microbiome profiling and LC-MS/MS for plasma metabolomics. Causal mediation analysis and Cox proportional hazards models were used to assess microbial mediation of metabolite changes and mortality associations.
Main Finding
Age-associated gut microbial taxa (e.g., Oscillibacter, Firmicutes decline, Proteobacteria increase) mediate over 200 plasma metabolites, with specific metabolites (e.g., Glycoursodeoxycholic acid, Triacylglyceride 18:0_34:3) significantly associated with increased all-cause mortality.
Confidence Level
Moderate; findings are robust within the cohort but limited by cross-sectional microbiome-metabolite measurements and lack of replication cohort.
Study Flags
Red Flags
- •Cross-sectional microbiome-metabolite measurements limit causal inference
- •Cohort is predominantly healthy, high-SES individuals, limiting generalizability
- •No independent replication cohort
Surprising Findings
Gut microbiome diversity increases with age—and that’s linked to longevity.
Most assume aging means losing microbial diversity, but here, older, healthier adults had higher diversity—challenging the idea that 'less diversity = aging.'
Practical Takeaways
Eat more diverse plant fibers to support beneficial genera like Faecalibacterium and possibly suppress Oscillibacter.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study found that older people tend to have different gut bacteria and blood chemicals than younger people, and that some of these chemicals are linked to whether people live longer or not. But it doesn't prove that the bacteria cause the chemicals to change or that changing the bacteria will make you live longer.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large, well-characterized longitudinal cohort (BLSA) with detailed phenotyping
- Use of standardized, high-quality metabolomic and microbiome profiling methods
- Adjustment for key confounders (age, sex, race) in statistical models
Weaknesses
- Cross-sectional measurement of microbiome and metabolites (no temporal sequence)
- No control for diet, medication, or lifestyle factors that strongly influence microbiome and metabolites
- Targeted metabolite panel may miss important unmeasured metabolites
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
As people get older, the types of bacteria in their gut change, and these bacteria affect chemicals in the blood that can make you more or less likely to die.
Research results
6 bacterial types increased with age; 3 blood chemicals lowered death risk; 6 blood chemicals raised death risk.
What this means - more context
Yes—these chemical changes are linked to real differences in how long people live, even among healthy older adults.
This study investigates how age-related changes in the gut microbiome influence plasma metabolites and their association with all-cause mortality in healthy adults aged 27–98.
The study identifies age-associated shifts in gut microbial phyla and genera, which mediate changes in plasma metabolites—including bile acids, triglycerides, and phosphatidylcholines—linked to mortality risk. Three metabolites (Asparagine, Sphingomyelin C26:0, Dihydroceramide d18:0/24:1) were protective, while six (e.g., Glycoursodeoxycholic acid, specific triglycerides) increased mortality risk.
Methods Used
Observational cohort study of 704 participants from the Baltimore Longitudinal Study of Aging (BLSA) with shotgun metagenomics for gut microbiome profiling and LC-MS/MS for plasma metabolomics. Causal mediation analysis and Cox proportional hazards models were used to assess microbial mediation of metabolite changes and mortality associations.
Main Finding
Age-associated gut microbial taxa (e.g., Oscillibacter, Firmicutes decline, Proteobacteria increase) mediate over 200 plasma metabolites, with specific metabolites (e.g., Glycoursodeoxycholic acid, Triacylglyceride 18:0_34:3) significantly associated with increased all-cause mortality.
Confidence Level
Moderate; findings are robust within the cohort but limited by cross-sectional microbiome-metabolite measurements and lack of replication cohort.
Study Flags
Red Flags
- •Cross-sectional microbiome-metabolite measurements limit causal inference
- •Cohort is predominantly healthy, high-SES individuals, limiting generalizability
- •No independent replication cohort
Surprising Findings
Gut microbiome diversity increases with age—and that’s linked to longevity.
Most assume aging means losing microbial diversity, but here, older, healthier adults had higher diversity—challenging the idea that 'less diversity = aging.'
Practical Takeaways
Eat more diverse plant fibers to support beneficial genera like Faecalibacterium and possibly suppress Oscillibacter.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study found that older people tend to have different gut bacteria and blood chemicals than younger people, and that some of these chemicals are linked to whether people live longer or not. But it doesn't prove that the bacteria cause the chemicals to change or that changing the bacteria will make you live longer.
No conflicts of interest were detected in this study. No score impact.
Strengths
- Large, well-characterized longitudinal cohort (BLSA) with detailed phenotyping
- Use of standardized, high-quality metabolomic and microbiome profiling methods
- Adjustment for key confounders (age, sex, race) in statistical models
Weaknesses
- Cross-sectional measurement of microbiome and metabolites (no temporal sequence)
- No control for diet, medication, or lifestyle factors that strongly influence microbiome and metabolites
- Targeted metabolite panel may miss important unmeasured metabolites
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The scientists used a really good group of healthy older adults and measured their gut bacteria and blood chemicals very carefully. But they didn't change anything or control what people ate or did, so we can't be sure if the bacteria are the cause—or if something else, like diet, is responsible.
40 / 100
- COI disclosure+40/40
- Data availabilitydata not shared
- Code availabilitycode not shared
37 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control groupno control group
- Sample size (n=704)+19.4/20
- Follow-up+10/10
100 / 100
77 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registrationnot pre-registered
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 560 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization or intervention; it can identify associations but cannot determine if changes in gut microbiota cause changes in metabolites or mortality, as reverse causation and confounding factors (e.g., diet, medications, lifestyle) cannot be ruled out.
No Conflicts
No conflicts of interest identified
No conflicts of interest or funding disclosures were reported in the study text.
The study was conducted using data from the Baltimore Longitudinal Study of Aging (BLSA), which is supported by the National Institute on Aging (NIA), an entity of the National Institutes of Health (NIH). However, no explicit funding statement or conflict of interest disclosure was provided in the text. The methods describe standard academic protocols and third-party labs (Diversigen, Biocrates) for sequencing and metabolite analysis, with no indication of industry influence on study design, analysis, or publication. No author affiliations with commercial entities are disclosed.